申请人:Harris Neil Victor
公开号:US20090221604A1
公开(公告)日:2009-09-03
A compound for use as a PGD2 antagonist is of structural formula [1] in which: A represents a fully saturated or partially unsaturated monocyclic 5-7 membered ring containing one or two nitrogen atoms; B represents a direct bond, an optionally substituted methylene group, an optionally substituted nitrogen atom, oxygen, or S(O)
n
, where n=0, 1, or 2; L represents a direct bond, or an optionally substituted alkylene or alkenylene group; R
1
represents an optionally substituted aryl or heteroaryl group, or an optionally substituted aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl group; R
2
represents an optionally substituted aryl or heteroaryl group, or an optionally substituted aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl group; X represents a carboxylic acid, tetrazole, 3-hydroxyisoxazole, hydroxamic acid, phosphinate, phosphonate, phosphonamide, sulfonic acid or a group of formula C(═O)NHSO
2
Y or SO
2
NHC(═O)Y; and Y represents an optionally substituted aryl or heteroaryl group or an optionally substituted alkyl or cycloalkyl group; or a N-oxide, pharmaceutically acceptable salt, solvate or prodrug thereof.
可用作PGD2拮抗剂的化合物具有结构式[1],其中:A代表一个完全饱和或部分不饱和的单环5-7成员环,其中包含一个或两个氮原子;B代表直接键,可选择性取代的亚甲基基团,可选择性取代的氮原子、氧或S(O)n,其中n = 0、1或2;L代表直接键或可选择性取代的烷基或烯基基团;R1代表可选择性取代的芳基或杂环芳基基团,或可选择性取代的芳基融合杂环烷基、杂环芳基融合环烷基、杂环芳基融合杂环烷基或芳基融合环烷基基团;R2代表可选择性取代的芳基或杂环芳基基团,或可选择性取代的芳基融合杂环烷基、杂环芳基融合环烷基、杂环芳基融合杂环烷基或芳基融合环烷基基团;X代表羧酸、四唑、3-羟基异噁唑、羟肟酸、磷酸酯、膦酸酯、膦酰胺、磺酸或式C(═O)NHSO2Y或SO2NHC(═O)Y的基团;Y代表可选择性取代的芳基或杂环芳基基团或可选择性取代的烷基或环烷基基团;或其N-氧化物、药学上可接受的盐、溶剂合物或前药。